Syngenta receives approval for breakthrough fungicide ADEPIDYN™ in Argentina


Basel, Switzerland

  • First registration of a product based on ADEPIDYN™
  • Global peak sales potential estimated at more than $750 million
  • ADEPIDYN™ based products to be marketed under the MIRAVIS™ brand 

Syngenta announced today that MIRAVIS™ Duo, a combination of ADEPIDYN™ and difenoconazole, has been approved by SENASA (regulatory authority in Argentina),  for use on soybean for late cycle diseases. This is the first registration for a product based on ADEPIDYN™, a new fungicide belonging to the carboxamide chemical class.

ADEPIDYN™ provides a step change in leaf spot disease management and delivers excellent control of powdery mildew. It is highly effective on difficult-to-control diseases such as Fusarium head blight and moulds which cause severe damage to the crop. Syngenta is currently developing several ADEPIDYN™ based products to address various disease management challenges in soybean, wheat, corn, canola, vegetables and specialty crops around the world.

Jon Parr, President Global Crop Protection, Syngenta, said “MIRAVIS™ Duo builds on our strong fungicide heritage including ELATUS™ and AMISTAR® Technology. By continuing to deliver industry-leading innovation to growers, we are strengthening our global leadership in fungicides.”

First sales of MIRAVIS™ Duo are expected in the 2016/2017 soybean season in Argentina. Regulatory approvals are pending in several other markets.

About Syngenta

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 28,000 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit and Follow us on Twitter® at

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Corporate Contacts

Media Office

Leandro Conti
Tel: +41 61 323 2323
Fax: +41 61 323 2424

Paul Minehart
Tel: +1 202 737 8913

Investor Relations

Jennifer Gough
Switzerland +41 61 323 5059
USA +1 202 737 6521

Corporate Responsibility

Shareholder Contacts

Shareholder Services
Syngenta AG
P.O. Box
CH-4002 Basel

Tel: +41 (0)61 323 2121
Fax: +41 (0)61 323 5461

Note: To add/edit content, please navigate through the Advanced Editing visible in the ribbon at the top.

Find it here

Expand all